Efficacy and safety of adalimumab in ankylosing spondylitis.

about

Pulmonary Sarcoidosis following Etanercept Treatment for Ankylosing Spondylitis: A Case Report and Review of the Literature.Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

P2860

Q53696500-B538B716-F2B9-425C-835C-AE1F990F2F7F Q57167308-8680E66A-0B5F-4788-BF59-2C8EA368C7D3

P2860

Efficacy and safety of adalimumab in ankylosing spondylitis.

Item

http://www.wikidata.org/entity/Q38993324

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Efficacy and safety of adalimumab in ankylosing spondylitis.

@en

type

Item

label

Efficacy and safety of adalimumab in ankylosing spondylitis.

@en

prefLabel

Efficacy and safety of adalimumab in ankylosing spondylitis.

@en

P1476

Efficacy and safety of adalimumab in ankylosing spondylitis.

@en

P2093

Abdellah El Maghraoui

http://www.w3.org/2001/XMLSchema#string

Aziza Mounach

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Assessment of enthesitis in ankylosing spondylitis.

Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system.

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.

P304

83-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OARRR.S44550

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27790037

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

P932

5045114

http://www.w3.org/2001/XMLSchema#string

Efficacy and safety of adalimumab in ankylosing spondylitis.

about

P2860

P2860

Efficacy and safety of adalimumab in ankylosing spondylitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932